Fig. 1
CT1812 treatment results in increases in CSF Aβ oligomers, but not monomers, in an exposure-dependent manner. a Subject demographics. b–g CSF Aβ oligomer or monomer concentrations were measured in individual AD patient samples collected hourly before (− 4 to 0 h as baseline) and 24 h after a single dose of 560 mg CT1812 or placebo. Aβ monomers (ELISA) increased by < 50% of baseline during the post-dose period, but Aβ oligomers (MIE) increased by > 250% (Patient 3) and > 500% (Patient 1) of baseline (b–d). Non-denaturing western blotting revealed similar increases of CSF Aβ oligomers in CT1812 patients (e–g). h The oligomer level by western blot correlated with that measured by MIE (Pearson r = 0.74; n = 70 samples) i CSF total exposure levels of CT1812 (data shown in Table S1) were related to the total AUC0-last of CSF Aβ oligomer concentration (MIE or Western blot) across patients